NCT00975299终止1 期
Open-label, Multicenter PET/CT (Positron Emission Tomography/Computed Tomography) Study for Investigation of Safety, Tolerability, Biodistribution and Diagnostic Performance of the 18F Labeled PET Tracer BAY86-4367 Following a Single Intravenous Administration of 300 MBq (Corresponding to </= 40 µg Mass Dose) in Patients With Prostate Cancer as Well as Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability of the Tracer in PET/CT in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Bayer
- 入组人数
- 16
- 主要终点
- Visual assessment of lesions
研究概览
简要总结
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-4367 in patients with cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Healthy volunteers:
- •males, >/=50 and <= 65 years of age
- •Cancer patients:
- •males >/= 45 years of age
- •patients with recurrent prostate cancer had a positive choline PET/CT for detection, or staging, or restaging of cancer, evaluation of the primary prostate cancer detection rate with BAY 86-4367 in comparison to histology as standard of truth (choline PET/CT is optional).
排除标准
- •Exclusion criteria for all healthy volunteers and patients:
- •Concurrent severe and/or uncontrolled and/or unstable other medical disease (e.g. poorly controlled diabetes, congestive heart failure, myocardial infarction within 12 months prior to planned injection of BAY 86-4367, unstable and uncontrolled hypertension, chronic renal or hepatic disease, severe pulmonary disease) which could compromise participation in the study
- •Known sensitivity to the study drug or components of the preparation.
研究组 & 干预措施
Arm 1
Experimental
干预措施: BAY86-4367 (Drug)
Arm 2
Experimental
干预措施: BAY86-4367 (Drug)
结局指标
主要结局
Visual assessment of lesions
时间窗: Day of study drug administration
次要结局
- Electrocardiogram (ECG)(At least 3 times within 8 days after treatment)
- Serum creatinine(At least 3 times within 8 days after treatment)
- Serum GOT (Glutamat-Oxalacetat-Transaminase)(At least 3 times within 8 days after treatment)
- Adverse events collection(At least 3 times within 8 days after treatment)
- Blood pressure(At least 3 times within 8 days after treatment)
- Serum protein(At least 3 times within 8 days after treatment)
- Quantitative analysis of BAY86-4367 uptake into lesions (Standardized Uptake Values = SUVs)(Day of study drug administration)
研究者
相似试验
已完成
1 期
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy VolunteersDiagnostic ImagingNCT01205321Life Molecular Imaging SA19
已完成
1 期
Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or InflammationDiagnostic ImagingNeoplasmsNCT01103310Life Molecular Imaging SA46
进行中（未招募）
1 期
PET/CT (positron emission tomography/computed tomography) imaging using [68Ga]RM2 (radioactive PET tracer) for detection of tumors in patients with primary prostate cancer.Patients with primary prostate cancer in which prostate cancer is histologically confirmed and a prostatectomy is planned.MedDRA version: 18.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003027-21-ATPiramal Imaging SA80
进行中（未招募）
1 期
PET/CT (positron emission tomography/computed tomography) imaging using [68Ga]RM2 (radioactive PET tracer) for detection of tumors in patients with primary prostate cancer.Patients with primary prostate cancer in which prostate cancer is histologically confirmed and a prostatectomy is planned.MedDRA version: 18.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003027-21-FIPiramal Imaging SA80
已完成
1 期
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With InflammationsDiagnostic ImagingNCT01089998Life Molecular Imaging SA35